Abzena's antibody moves to phase two trial
One of life-science company Abzena’s composite human antibody is to move to a phase two clinical trial.
Abzena
15.75p
16:24 11/10/18
Pharmaceuticals & Biotechnology
22,093.96
09:00 07/10/24
The AIM-listed company’s 'Abzena inside' composite human antibody products, which are being developed by a US pharmaceutical to treat neurodegenerative conditions, is to move to a stage-two clinical trial after being studied in two phase one clinical trials.
‘Abzena inside’ products, which the company has the potential to earn future licence fees, milestone payments and royalties on, are products such as composite human antibodies and ThioBridge antibody drug conjugate created using Abzena’s technologies and are developed by its partners.
Abzena chief executive Dr John Burt said: "We are pleased to see the progression of this 'Abzena inside' product into phase two clinical development following the recent similar announcements about two other 'Abzena inside' products.
“This illustrates the strength we have in the portfolio of products that our partners are developing based on our antibody engineering technology."
Shares in Abzena were up 3.84% to 37.90p at 0807 GMT.